Jonathan M. Mansbach, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bronchiolitis | 85 | 2022 | 406 | 15.630 |
Why?
|
| Respiratory Syncytial Virus Infections | 29 | 2022 | 295 | 6.030 |
Why?
|
| Bronchiolitis, Viral | 16 | 2021 | 74 | 4.680 |
Why?
|
| Picornaviridae Infections | 15 | 2021 | 92 | 3.880 |
Why?
|
| Rhinovirus | 22 | 2022 | 168 | 3.840 |
Why?
|
| Respiratory Sounds | 16 | 2021 | 682 | 3.180 |
Why?
|
| Respiratory Syncytial Viruses | 11 | 2020 | 156 | 2.800 |
Why?
|
| Nasopharynx | 21 | 2022 | 389 | 2.670 |
Why?
|
| Respiratory Syncytial Virus, Human | 10 | 2022 | 115 | 2.670 |
Why?
|
| Respiratory Tract Infections | 9 | 2022 | 969 | 2.340 |
Why?
|
| Hospitalization | 40 | 2022 | 9718 | 1.720 |
Why?
|
| Infant | 99 | 2022 | 34497 | 1.540 |
Why?
|
| Asthma | 23 | 2022 | 5909 | 1.340 |
Why?
|
| Nasal Cavity | 3 | 2018 | 307 | 1.090 |
Why?
|
| Moraxella | 5 | 2019 | 26 | 1.080 |
Why?
|
| Antimicrobial Cationic Peptides | 3 | 2017 | 356 | 1.060 |
Why?
|
| Length of Stay | 17 | 2020 | 6278 | 1.010 |
Why?
|
| Nasal Mucosa | 4 | 2019 | 368 | 0.990 |
Why?
|
| Croup | 1 | 2022 | 25 | 0.920 |
Why?
|
| Haemophilus | 4 | 2019 | 30 | 0.880 |
Why?
|
| Trachea | 2 | 2018 | 1085 | 0.860 |
Why?
|
| Common Cold | 5 | 2020 | 61 | 0.850 |
Why?
|
| RNA, Ribosomal, 16S | 5 | 2020 | 909 | 0.850 |
Why?
|
| Coronavirus | 2 | 2020 | 151 | 0.830 |
Why?
|
| Streptococcus | 3 | 2019 | 205 | 0.810 |
Why?
|
| Apnea | 2 | 2019 | 196 | 0.770 |
Why?
|
| Metabolome | 12 | 2021 | 866 | 0.770 |
Why?
|
| Erythema | 1 | 2021 | 263 | 0.760 |
Why?
|
| Child, Hospitalized | 1 | 2021 | 181 | 0.740 |
Why?
|
| Bronchodilator Agents | 6 | 2018 | 510 | 0.740 |
Why?
|
| Staphylococcus | 3 | 2018 | 143 | 0.730 |
Why?
|
| Vitamin D Deficiency | 8 | 2018 | 1367 | 0.710 |
Why?
|
| Vitamin D | 11 | 2018 | 3163 | 0.670 |
Why?
|
| Tracheostomy | 2 | 2018 | 400 | 0.660 |
Why?
|
| Biofilms | 1 | 2022 | 601 | 0.650 |
Why?
|
| Emergency Service, Hospital | 13 | 2018 | 7481 | 0.630 |
Why?
|
| Prospective Studies | 56 | 2022 | 51181 | 0.630 |
Why?
|
| Serum Albumin | 1 | 2019 | 682 | 0.590 |
Why?
|
| Infant, Premature, Diseases | 1 | 2021 | 699 | 0.560 |
Why?
|
| Aftercare | 1 | 2020 | 705 | 0.540 |
Why?
|
| Critical Care | 7 | 2019 | 2493 | 0.530 |
Why?
|
| Nasopharyngitis | 1 | 2013 | 7 | 0.520 |
Why?
|
| Pharynx | 2 | 2016 | 419 | 0.520 |
Why?
|
| Depression, Postpartum | 1 | 2018 | 310 | 0.510 |
Why?
|
| Proteobacteria | 1 | 2013 | 46 | 0.510 |
Why?
|
| Child, Preschool | 30 | 2021 | 41181 | 0.490 |
Why?
|
| Severity of Illness Index | 23 | 2020 | 16011 | 0.480 |
Why?
|
| Infant, Newborn | 27 | 2021 | 24645 | 0.470 |
Why?
|
| Climate | 1 | 2012 | 124 | 0.440 |
Why?
|
| Altitude | 1 | 2012 | 141 | 0.430 |
Why?
|
| Cross Infection | 1 | 2021 | 1410 | 0.430 |
Why?
|
| Humans | 120 | 2022 | 715124 | 0.420 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2012 | 443 | 0.420 |
Why?
|
| Male | 84 | 2021 | 351081 | 0.410 |
Why?
|
| Female | 86 | 2021 | 377334 | 0.400 |
Why?
|
| Haemophilus influenzae | 3 | 2022 | 178 | 0.390 |
Why?
|
| Respiratory System | 3 | 2022 | 560 | 0.390 |
Why?
|
| Patient Discharge | 4 | 2015 | 3010 | 0.390 |
Why?
|
| Continuous Positive Airway Pressure | 3 | 2017 | 549 | 0.360 |
Why?
|
| Child | 26 | 2022 | 74146 | 0.350 |
Why?
|
| Viral Load | 4 | 2021 | 3232 | 0.350 |
Why?
|
| Metapneumovirus | 1 | 2008 | 20 | 0.340 |
Why?
|
| Cohort Studies | 26 | 2021 | 39804 | 0.320 |
Why?
|
| Medical Staff, Hospital | 1 | 2012 | 628 | 0.320 |
Why?
|
| Multicenter Studies as Topic | 3 | 2019 | 1529 | 0.310 |
Why?
|
| Eczema | 2 | 2021 | 204 | 0.310 |
Why?
|
| Sequence Analysis, DNA | 2 | 2018 | 4910 | 0.310 |
Why?
|
| Feces | 3 | 2017 | 1382 | 0.300 |
Why?
|
| Office Visits | 2 | 2010 | 633 | 0.300 |
Why?
|
| Ethics Committees, Research | 1 | 2007 | 162 | 0.290 |
Why?
|
| Molecular Typing | 3 | 2021 | 118 | 0.280 |
Why?
|
| Spermatic Cord Torsion | 1 | 2005 | 75 | 0.280 |
Why?
|
| Intensive Care Units | 7 | 2020 | 3441 | 0.280 |
Why?
|
| Urinary Tract Infections | 2 | 2021 | 780 | 0.270 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 3276 | 0.270 |
Why?
|
| United States | 34 | 2022 | 67665 | 0.260 |
Why?
|
| Influenza A virus | 1 | 2008 | 453 | 0.260 |
Why?
|
| Intubation, Intratracheal | 1 | 2012 | 1327 | 0.250 |
Why?
|
| Pandemics | 2 | 2020 | 7213 | 0.250 |
Why?
|
| Risk Factors | 23 | 2022 | 70704 | 0.250 |
Why?
|
| Orchiectomy | 1 | 2005 | 456 | 0.240 |
Why?
|
| Emergency Medicine | 3 | 2012 | 1186 | 0.240 |
Why?
|
| Metabolic Networks and Pathways | 2 | 2018 | 820 | 0.230 |
Why?
|
| Recurrence | 6 | 2021 | 8269 | 0.230 |
Why?
|
| Albuterol | 2 | 2018 | 211 | 0.230 |
Why?
|
| Incidence | 9 | 2021 | 20596 | 0.220 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3158 | 0.220 |
Why?
|
| Hospitals, Psychiatric | 1 | 2003 | 331 | 0.220 |
Why?
|
| Child Health Services | 1 | 2007 | 676 | 0.210 |
Why?
|
| Antiviral Agents | 3 | 2015 | 2794 | 0.210 |
Why?
|
| Viruses | 2 | 2022 | 357 | 0.200 |
Why?
|
| Chemokine CCL5 | 2 | 2018 | 215 | 0.200 |
Why?
|
| Clinical Protocols | 1 | 2007 | 1472 | 0.200 |
Why?
|
| Blood Sedimentation | 1 | 2021 | 231 | 0.200 |
Why?
|
| Optic Nerve Diseases | 1 | 2003 | 320 | 0.190 |
Why?
|
| Immunoglobulin E | 3 | 2022 | 1494 | 0.190 |
Why?
|
| Sphingolipids | 2 | 2020 | 167 | 0.190 |
Why?
|
| Endemic Diseases | 1 | 2020 | 159 | 0.190 |
Why?
|
| Streptococcus pneumoniae | 3 | 2022 | 774 | 0.180 |
Why?
|
| Multivariate Analysis | 10 | 2018 | 12477 | 0.180 |
Why?
|
| Coxsackievirus Infections | 1 | 2019 | 51 | 0.180 |
Why?
|
| Enterovirus | 1 | 2019 | 66 | 0.180 |
Why?
|
| Hospitals, Pediatric | 4 | 2020 | 1780 | 0.170 |
Why?
|
| Seasons | 4 | 2019 | 1427 | 0.170 |
Why?
|
| Ambulatory Care | 3 | 2015 | 2773 | 0.170 |
Why?
|
| Cellulitis | 1 | 2020 | 233 | 0.170 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 2021 | 422 | 0.170 |
Why?
|
| Lyme Disease | 1 | 2003 | 606 | 0.170 |
Why?
|
| Environmental Exposure | 1 | 2012 | 4046 | 0.170 |
Why?
|
| Nose | 1 | 2021 | 493 | 0.160 |
Why?
|
| Virus Diseases | 2 | 2015 | 684 | 0.160 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2019 | 289 | 0.160 |
Why?
|
| Time Factors | 4 | 2020 | 41081 | 0.160 |
Why?
|
| Finland | 4 | 2021 | 604 | 0.150 |
Why?
|
| DNA, Ribosomal | 1 | 2018 | 312 | 0.150 |
Why?
|
| Logistic Models | 8 | 2015 | 13594 | 0.150 |
Why?
|
| Health Care Surveys | 4 | 2012 | 2509 | 0.150 |
Why?
|
| Guideline Adherence | 1 | 2007 | 2333 | 0.150 |
Why?
|
| Headache | 1 | 2003 | 1142 | 0.140 |
Why?
|
| Age Distribution | 3 | 2008 | 2927 | 0.140 |
Why?
|
| Metabolomics | 3 | 2020 | 1379 | 0.140 |
Why?
|
| Bordetella pertussis | 1 | 2015 | 42 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 7480 | 0.140 |
Why?
|
| Phenobarbital | 1 | 1996 | 186 | 0.140 |
Why?
|
| Intensive Care Units, Pediatric | 2 | 2019 | 971 | 0.140 |
Why?
|
| Treatment Outcome | 11 | 2020 | 62186 | 0.140 |
Why?
|
| Whooping Cough | 1 | 2015 | 80 | 0.130 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 1996 | 203 | 0.130 |
Why?
|
| Disease | 1 | 2020 | 703 | 0.130 |
Why?
|
| Pediatrics | 2 | 2007 | 3553 | 0.130 |
Why?
|
| Longitudinal Studies | 3 | 2020 | 13573 | 0.130 |
Why?
|
| Polymerase Chain Reaction | 3 | 2015 | 6290 | 0.130 |
Why?
|
| Statistics, Nonparametric | 1 | 2020 | 2936 | 0.130 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 1996 | 318 | 0.130 |
Why?
|
| Gastroesophageal Reflux | 1 | 2020 | 717 | 0.130 |
Why?
|
| Nonprescription Drugs | 1 | 2015 | 117 | 0.130 |
Why?
|
| Blood Proteins | 1 | 2019 | 1145 | 0.130 |
Why?
|
| Geography | 2 | 2007 | 690 | 0.120 |
Why?
|
| Carcinogens | 1 | 1996 | 452 | 0.120 |
Why?
|
| Saline Solution, Hypertonic | 1 | 2014 | 140 | 0.120 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2014 | 1847 | 0.120 |
Why?
|
| Snow | 1 | 2012 | 14 | 0.120 |
Why?
|
| Wind | 1 | 2012 | 35 | 0.120 |
Why?
|
| Rain | 1 | 2012 | 57 | 0.120 |
Why?
|
| Gestational Age | 1 | 2021 | 3414 | 0.120 |
Why?
|
| DNA, Bacterial | 1 | 2018 | 1527 | 0.110 |
Why?
|
| Siblings | 1 | 2016 | 814 | 0.110 |
Why?
|
| Patient Admission | 3 | 2010 | 1401 | 0.110 |
Why?
|
| Hyponatremia | 1 | 2015 | 306 | 0.110 |
Why?
|
| Infant, Premature | 1 | 2021 | 2007 | 0.110 |
Why?
|
| Humidity | 1 | 2012 | 189 | 0.110 |
Why?
|
| Food Hypersensitivity | 1 | 2019 | 628 | 0.110 |
Why?
|
| Respiration, Artificial | 4 | 2015 | 2452 | 0.110 |
Why?
|
| Cytokines | 3 | 2019 | 7225 | 0.110 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2015 | 2316 | 0.110 |
Why?
|
| Confidence Intervals | 3 | 2010 | 2973 | 0.110 |
Why?
|
| Social Behavior | 1 | 2018 | 1111 | 0.110 |
Why?
|
| Proportional Hazards Models | 3 | 2021 | 12404 | 0.110 |
Why?
|
| Adolescent | 11 | 2018 | 84999 | 0.110 |
Why?
|
| Cough | 1 | 2015 | 557 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 2 | 2015 | 9584 | 0.100 |
Why?
|
| Hospital Charges | 1 | 2013 | 361 | 0.100 |
Why?
|
| Acute Disease | 2 | 2019 | 7177 | 0.100 |
Why?
|
| Prevalence | 4 | 2020 | 14869 | 0.100 |
Why?
|
| Positive-Pressure Respiration | 3 | 2020 | 598 | 0.100 |
Why?
|
| Research Design | 1 | 2007 | 5876 | 0.100 |
Why?
|
| Sex Distribution | 2 | 2008 | 2366 | 0.100 |
Why?
|
| Epinephrine | 1 | 2014 | 811 | 0.100 |
Why?
|
| Risk Assessment | 4 | 2020 | 23511 | 0.100 |
Why?
|
| Follow-Up Studies | 6 | 2020 | 39285 | 0.100 |
Why?
|
| Cross-Sectional Studies | 8 | 2019 | 23283 | 0.100 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2015 | 629 | 0.100 |
Why?
|
| Retrospective Studies | 7 | 2021 | 72255 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 4 | 2014 | 7045 | 0.090 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2015 | 806 | 0.090 |
Why?
|
| C-Reactive Protein | 1 | 2021 | 3707 | 0.090 |
Why?
|
| Statistics as Topic | 2 | 2014 | 2406 | 0.090 |
Why?
|
| Prevotella | 2 | 2020 | 82 | 0.090 |
Why?
|
| NF-kappa B | 1 | 2018 | 2579 | 0.090 |
Why?
|
| Bacterial Infections | 1 | 2017 | 1426 | 0.090 |
Why?
|
| Pregnancy Complications | 2 | 2015 | 2827 | 0.090 |
Why?
|
| Tennessee | 1 | 2008 | 126 | 0.090 |
Why?
|
| Models, Statistical | 2 | 2020 | 5028 | 0.090 |
Why?
|
| Smoking | 3 | 2015 | 8932 | 0.090 |
Why?
|
| Communicable Diseases | 1 | 2016 | 796 | 0.090 |
Why?
|
| Drug Utilization | 2 | 2012 | 1223 | 0.090 |
Why?
|
| Models, Theoretical | 1 | 2020 | 3563 | 0.080 |
Why?
|
| Bacteria | 1 | 2018 | 2083 | 0.080 |
Why?
|
| Massachusetts | 1 | 2020 | 8734 | 0.080 |
Why?
|
| Proteome | 3 | 2022 | 1770 | 0.080 |
Why?
|
| Health Surveys | 2 | 2009 | 4021 | 0.080 |
Why?
|
| Parents | 1 | 2020 | 3160 | 0.080 |
Why?
|
| Health Insurance Portability and Accountability Act | 1 | 2007 | 99 | 0.080 |
Why?
|
| Disease Management | 3 | 2014 | 2534 | 0.070 |
Why?
|
| Causality | 1 | 2012 | 1177 | 0.070 |
Why?
|
| Probability | 2 | 2010 | 2480 | 0.070 |
Why?
|
| RNA, Viral | 1 | 2014 | 2831 | 0.070 |
Why?
|
| Drug Utilization Review | 1 | 2007 | 258 | 0.070 |
Why?
|
| Temperature | 1 | 2012 | 2158 | 0.070 |
Why?
|
| Appointments and Schedules | 1 | 2010 | 432 | 0.070 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 3695 | 0.070 |
Why?
|
| Workplace | 1 | 2012 | 856 | 0.070 |
Why?
|
| Young Adult | 6 | 2018 | 56155 | 0.070 |
Why?
|
| Insurance, Health | 2 | 2010 | 2496 | 0.070 |
Why?
|
| Interviews as Topic | 2 | 2009 | 2595 | 0.070 |
Why?
|
| Parathyroid Hormone | 1 | 2012 | 1814 | 0.070 |
Why?
|
| Glucocorticoids | 1 | 2014 | 2109 | 0.070 |
Why?
|
| Age Factors | 6 | 2020 | 18789 | 0.060 |
Why?
|
| Hospitals, County | 1 | 2003 | 18 | 0.060 |
Why?
|
| Mental Disorders | 1 | 2003 | 6423 | 0.060 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2005 | 358 | 0.060 |
Why?
|
| Disease Susceptibility | 2 | 2020 | 1785 | 0.060 |
Why?
|
| Leukocytosis | 1 | 2003 | 251 | 0.060 |
Why?
|
| Premature Birth | 1 | 2013 | 1529 | 0.060 |
Why?
|
| MicroRNAs | 1 | 2018 | 3674 | 0.050 |
Why?
|
| Intracranial Pressure | 1 | 2003 | 327 | 0.050 |
Why?
|
| Prognosis | 3 | 2015 | 29168 | 0.050 |
Why?
|
| Pregnancy | 4 | 2020 | 27180 | 0.050 |
Why?
|
| Nausea | 1 | 2003 | 658 | 0.050 |
Why?
|
| Predictive Value of Tests | 3 | 2020 | 15258 | 0.050 |
Why?
|
| Lipid Metabolism | 2 | 2020 | 2003 | 0.050 |
Why?
|
| Vomiting | 1 | 2003 | 628 | 0.050 |
Why?
|
| Pneumonia | 1 | 2012 | 2094 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 13268 | 0.050 |
Why?
|
| Cluster Analysis | 2 | 2017 | 2746 | 0.050 |
Why?
|
| Radiography | 2 | 2014 | 6994 | 0.050 |
Why?
|
| Carnitine | 1 | 2020 | 234 | 0.050 |
Why?
|
| Anorexia Nervosa | 1 | 2008 | 1331 | 0.040 |
Why?
|
| Quality Indicators, Health Care | 1 | 2009 | 1832 | 0.040 |
Why?
|
| Insurance Coverage | 1 | 2010 | 1863 | 0.040 |
Why?
|
| Adult | 7 | 2017 | 212129 | 0.040 |
Why?
|
| Boston | 1 | 2012 | 9400 | 0.040 |
Why?
|
| Calcium | 1 | 2012 | 5818 | 0.040 |
Why?
|
| African Americans | 2 | 2014 | 5065 | 0.040 |
Why?
|
| Odds Ratio | 3 | 2016 | 9968 | 0.040 |
Why?
|
| Decision Trees | 1 | 2020 | 523 | 0.040 |
Why?
|
| Host-Pathogen Interactions | 2 | 2019 | 1488 | 0.040 |
Why?
|
| Corynebacterium | 1 | 2017 | 48 | 0.040 |
Why?
|
| Health Care Costs | 2 | 2013 | 3171 | 0.040 |
Why?
|
| Interferon-alpha | 1 | 2022 | 897 | 0.040 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2020 | 472 | 0.040 |
Why?
|
| Poisson Distribution | 1 | 2018 | 515 | 0.040 |
Why?
|
| Diethylnitrosamine | 1 | 1996 | 39 | 0.040 |
Why?
|
| Expectorants | 1 | 2015 | 18 | 0.040 |
Why?
|
| Mycoplasma pneumoniae | 1 | 2015 | 42 | 0.040 |
Why?
|
| Antitussive Agents | 1 | 2015 | 17 | 0.040 |
Why?
|
| Nasal Decongestants | 1 | 2015 | 29 | 0.040 |
Why?
|
| Regression Analysis | 2 | 2020 | 6480 | 0.030 |
Why?
|
| Safety-Based Drug Withdrawals | 1 | 2015 | 44 | 0.030 |
Why?
|
| High-Frequency Ventilation | 1 | 2015 | 87 | 0.030 |
Why?
|
| Case-Control Studies | 3 | 2017 | 21790 | 0.030 |
Why?
|
| Intubation | 1 | 2015 | 140 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2005 | 2631 | 0.030 |
Why?
|
| Rats, Inbred F344 | 1 | 1996 | 883 | 0.030 |
Why?
|
| Multilevel Analysis | 1 | 2014 | 149 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2022 | 1748 | 0.030 |
Why?
|
| Fever | 1 | 2021 | 1589 | 0.030 |
Why?
|
| Blood Cell Count | 1 | 2014 | 420 | 0.030 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2020 | 1158 | 0.030 |
Why?
|
| Nutrition Surveys | 2 | 2010 | 1562 | 0.030 |
Why?
|
| Gene Expression Profiling | 2 | 2020 | 9521 | 0.030 |
Why?
|
| Disease Progression | 2 | 2019 | 13302 | 0.030 |
Why?
|
| Emergency Medical Services | 1 | 2003 | 1784 | 0.030 |
Why?
|
| Pre-Eclampsia | 1 | 2020 | 1108 | 0.030 |
Why?
|
| Mental Health Services | 1 | 2003 | 1608 | 0.030 |
Why?
|
| Utilization Review | 1 | 2013 | 401 | 0.030 |
Why?
|
| Hospitals, Community | 1 | 2013 | 336 | 0.030 |
Why?
|
| Catheterization, Peripheral | 1 | 2014 | 362 | 0.030 |
Why?
|
| Specimen Handling | 1 | 2015 | 695 | 0.030 |
Why?
|
| Infant, Low Birth Weight | 1 | 2015 | 845 | 0.020 |
Why?
|
| Hospital Costs | 1 | 2016 | 983 | 0.020 |
Why?
|
| Proteomics | 1 | 2022 | 3256 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2003 | 9022 | 0.020 |
Why?
|
| Community-Acquired Infections | 1 | 2012 | 473 | 0.020 |
Why?
|
| Socioeconomic Factors | 2 | 2014 | 7722 | 0.020 |
Why?
|
| Base Sequence | 1 | 2020 | 13315 | 0.020 |
Why?
|
| Gene Expression | 1 | 2021 | 8010 | 0.020 |
Why?
|
| Administration, Inhalation | 1 | 2010 | 1104 | 0.020 |
Why?
|
| Patient Transfer | 1 | 2015 | 764 | 0.020 |
Why?
|
| Radiography, Thoracic | 1 | 2014 | 1344 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2020 | 8042 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2022 | 3027 | 0.020 |
Why?
|
| Risk | 1 | 2019 | 9772 | 0.020 |
Why?
|
| Software | 1 | 2020 | 4350 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 2015 | 1745 | 0.020 |
Why?
|
| North America | 1 | 2008 | 1196 | 0.020 |
Why?
|
| Medically Uninsured | 1 | 2010 | 863 | 0.020 |
Why?
|
| Mothers | 1 | 2015 | 2013 | 0.020 |
Why?
|
| Emergencies | 1 | 2010 | 1124 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2016 | 10531 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 3565 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 2006 | 1660 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 1996 | 13292 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 14877 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2021 | 17395 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2018 | 12425 | 0.010 |
Why?
|
| Rats | 1 | 1996 | 25090 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2009 | 2707 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 19499 | 0.010 |
Why?
|
| Dietary Supplements | 1 | 2010 | 3078 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2009 | 2950 | 0.010 |
Why?
|
| Comorbidity | 1 | 2010 | 10423 | 0.010 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2009 | 3050 | 0.010 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2009 | 3033 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2018 | 23973 | 0.010 |
Why?
|
| Aged | 2 | 2012 | 162674 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2012 | 58505 | 0.000 |
Why?
|
| Middle Aged | 2 | 2012 | 214871 | 0.000 |
Why?
|
| Animals | 1 | 1996 | 170726 | 0.000 |
Why?
|